Short-term efficacy and safety of adding ezetimibe to currently used lipid-lowering drugs in Thai HIV-infected patients receiving protease inhibitors.

The objective of this study was to determine short-term efficacy and safety of adding ezetimibe to currently used statins. Thirty-two patients received ezetimibe 10 mg daily added to their ongoing lipid-lowering therapy for 18 weeks. Serum LDL-C, total cholesterol (TC), triglycerides (TG), TC/HDL-C ratio and HDL-C were measured at baseline, week 6, 12 and 18. Safety parameters were assessed by adverse event reports and laboratory assessments throughout the study. The mean percent change from baseline to endpoint in LDL-C, TC, TG and TC/HDL-C ratio were -23.3% (p < 0.001), -15.0% (p = 0.001), -22.1% (p = 0.004) and -16.2% (p = 0.018), respectively. No adverse event or other abnormal laboratory occurred. Addition of ezetimibe to currently used lipid-lowering drugs in HIV-infected patients receiving PIs who had not achieved goal of dyslipidemia therapy had significantly improved efficacy in reducing of LDL-C, TC, TG and TC/HDL-C ratio, and the therapy was safe and well tolerated. PMID: 29709973 [PubMed - as supplied by publisher]
Source: Japanese Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: Jpn J Infect Dis Source Type: research